| INSMED INC. DL-,01 |
| USA |
| Gesundheit |
| US4576693075 / A1JJA3 |
| IM8N (Frankfurt) / INSM (NASDAQ) |
| FRA:IM8N, ETR:IM8N, IM8N:GR, NASDAQ:INSM |
| - |
| https://insmed.com/ |
|
Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along..
>Volltext.. |
| 21558.77 Mio. EUR |
| 21197.67 Mio. EUR |
| 1010.69 Mio. EUR |
| -703.15 Mio. EUR |
| -777.64 Mio. EUR |
| -3.65 EUR |
| 663.89 Mio. EUR |
| 483.98 Mio. EUR |
| -692.01 Mio. EUR |
| 2.64 |
| 194.75% |
| 12.71% |
| - |
| - |
| - |
| INSMED |
| 05.10.26 |
|